Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2018
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2018
SUMMARY
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene.
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Central Nervous System and Ophthalmology which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Ischemic Stroke, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Peripheral Nerve Injury and Retinal Degeneration.
The latest report Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2018, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene.
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Central Nervous System and Ophthalmology which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Ischemic Stroke, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Peripheral Nerve Injury and Retinal Degeneration.
The latest report Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2018, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development
Copernicus Therapeutics Inc
Eli Lilly and Co
GlaxoSmithKline Plc
Treeway BV
UniQure NV
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles
AMT-090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GDNF for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-812 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAUR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAUR-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Activate GDNF for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smilagenin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TW-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones
Featured News & Press Releases
Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients
Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association
Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy
Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane
Feb 18, 2013: Phytopharm Announces Results from Parkinson’s Disease Clinical Trial of Cogane
Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis
Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson’s Disease
Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis
Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study
Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis
Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status
Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease
Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane
Apr 20, 2009: Phytopharm Announces the Commencement of Clinical Study of Cogane in Patients with Parkinson’s Disease
Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development
Copernicus Therapeutics Inc
Eli Lilly and Co
GlaxoSmithKline Plc
Treeway BV
UniQure NV
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles
AMT-090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GDNF for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-812 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAUR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAUR-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Activate GDNF for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smilagenin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TW-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones
Featured News & Press Releases
Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients
Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association
Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy
Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane
Feb 18, 2013: Phytopharm Announces Results from Parkinson’s Disease Clinical Trial of Cogane
Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis
Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson’s Disease
Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis
Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study
Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis
Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status
Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease
Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane
Apr 20, 2009: Phytopharm Announces the Commencement of Clinical Study of Cogane in Patients with Parkinson’s Disease
Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Copernicus Therapeutics Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Treeway BV, H2 2018
Pipeline by UniQure NV, H2 2018
Dormant Projects, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Copernicus Therapeutics Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Treeway BV, H2 2018
Pipeline by UniQure NV, H2 2018
Dormant Projects, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Copernicus Therapeutics Inc
Eli Lilly and Co
GlaxoSmithKline Plc
Treeway BV
UniQure NV
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Copernicus Therapeutics Inc
Eli Lilly and Co
GlaxoSmithKline Plc
Treeway BV
UniQure NV
